Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.41 |
| ▸ | CETP | P11597 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2407424 | 0.91 | MCHR1 (0.43) | DGAT1KCNH2CHRM4CETPHRH3 | |
| SCHEMBL2404039 | 0.89 | DGAT1 (0.41) | DGAT1KCNH2CHRM4HRH3 | |
| SCHEMBL2411687 | 0.89 | DGAT1 (0.41) | DGAT1KCNH2EGLN1HRH3 | |
| SCHEMBL2408002 | 0.88 | TRPM8 (0.41) | DGAT1CHRM4RETHRH3 | |
| SCHEMBL2411396 | 0.85 | CHRM4 (0.41) | DGAT1KCNH2CHRM4CETPCHRM2 | |
| SCHEMBL2406228 | 0.84 | AOC3 (0.41) | DGAT1KCNH2CHRM4 | |
| SCHEMBL2407642 | 0.84 | CNR2 (0.44) | DGAT1KCNH2EGLN1 | |
| SCHEMBL2431551 | 0.77 | MCHR1 (0.39) | DGAT1KCNH2CHRM4HRH3 | |
| SCHEMBL2406077 | 0.75 | PDE10A (0.45) | DGAT1KCNH2HRH3 | |
| SCHEMBL1711102 | 0.74 | CHRM4 (0.59) | DGAT1KCNH2CHRM4CETPCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912218-B2 | Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-12-16 | — | — | US | disclosed |
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MET, ALK, REL | DGAT1 4017/4885KCNH2 1681/4885CHRM4 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.